Posted by Michael Wonder on 25 Mar 2019
HIRA puts brakes on Gilead’s AIDS treatment receiving reimbursement
22 March 2019 - The reimbursement plan for Gilead Science Korea’s Biktarvy, an acquired immune deficiency syndrome (AIDS) treatment, has been put on hold due to the high price of the drug.
AbbVie’s Duobis intestinal gel, a treatment for Parkinson's disease, also failed to receive reimbursement because of unclear cost-effectiveness.
The Health Insurance Review and Assessment Service decided so after holding a health insurance policy review committee, which considered the appropriateness and reevaluation of the application for the medical treatments.
